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ardiorenal Effects of
ecombinant Human
atriuretic Peptides*
driaan A. Voors, MD, PHD,
irk J. van Veldhuisen, MD, PHD
roningen, the Netherlands
he cardiorenal syndrome describes the complex interaction
etween the kidney and the heart (1). This complex inter-
ction becomes particularly evident when we have to explain
he effects of intravenous recombinant human natriuretic
eptides (rhNPs) on renal function and outcome in patients
ith cardiovascular disease. Two examples of rhNPs are
ecombinant human B-type natriuretic peptide (BNP) (ne-
iritide) and recombinant human atrial natriuretic peptide
ANP) (carperitide). Carperitide was licensed in Japan in
995, and nesiritide was licensed in the U.S. in 2001, both
or the treatment of acute heart failure. Nesiritide and
arperitide both bind to the natriuretic peptide receptor A in
he heart, kidney, and other organs, mediating natriuresis,
nhibition of renin and aldosterone, as well as vasorelaxant,
nti-fibrotic, anti-hypertrophic, and lusitropic effects. No
ajor differences between carperitide and nesiritide have
een described. There is, however, continuing controversy
n the effects of both nesiritide and carperitide on renal
unction.
See page 1844
In 2005, a meta-analysis of 5 randomized studies with
,269 overall acute heart failure patients showed that intra-
enous nesiritide was associated with an increased risk of
orsening renal function (2). However, in a large, random-
zed, double-blind, placebo-controlled trial, serial infusions
f nesiritide were associated with a lower risk of worsening
enal function in severe, chronic heart failure patients with
enal impairment, although no effects on the primary end
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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roningen, the Netherlands. Dr. Voors receives consultancy honoraria for his
articipation in the Steering Committee of the ASCEND-HF trial (Acute Study of
linical Effectiveness of Nesiritide in Decompensated Heart Failure Trial), a trial onr
he effects of human recombinant B-type natriuretic peptide nesiritide in patients with
cute heart failure. Dr. van Veldhuisen has received consultancy fees from Biosite.oint of time to all-cause death or cardiovascular or renal
ospital stay at 12 weeks were observed (3).
Besides acute heart failure, intravenous rhNPs are cur-
ently also under investigation for perioperative use in
atients undergoing coronary bypass surgery. Coronary
ypass surgery has many similarities with acute heart failure,
uch as hemodynamic changes, volume overload, decreased
ardiac output, elevated filling pressures, and activation of
he renin-angiotensin-aldosterone system (RAAS) and
ympathetic nervous system, resulting in salt and water
etention. Also, similar to heart failure, renal dysfunction is
ery frequently found in patients undergoing coronary
ypass surgery and is clearly related to a poor outcome, both
n-hospital and during long-term follow-up (4,5). In 2006 it
as concluded, after several small studies, that the evidence
f the clinical benefit of nesiritide on renal function in
atients undergoing coronary bypass surgery was still con-
roversial (6). In 2007, results of a larger, randomized,
lacebo-controlled trial were published (7). In 272 coronary
ypass surgery patients with left ventricular dysfunction,
esiritide reduced the peak increase in serum creatinine,
educed the decrease in glomerular filtration rate (GFR),
ecreased the length of hospital stay, and lowered 180-day
ortality. However, due to the limited sample size and
ecause the mortality end point was added late in the study,
he authors concluded that this was an exploratory trial, and
hese data needed further confirmation.
In this issue of the Journal, Sezai at al. (8) indeed confirm
he data of the NAPA (Nesiritide Administered Peri-
nesthesia) trial in the NU-HIT (Nihon University work-
ng group study of low-dose Human ANP Infusion Therapy
uring cardiac surgery) trial. The NU-HIT randomized 133
oronary bypass surgery patients to rhANP or placebo
saline). Renal function was significantly better at 1 month
nd 6 and 12 months after surgery in the rhANP group
ompared with the placebo group. This was not accompa-
ied by a reduction in early postoperative mortality (first
rimary end point), but it was associated with less periop-
rative complications (second primary end point). However,
he sample size calculation was not properly justified, and
bviously this trial was too small to allow definite conclu-
ions about the effects of carperitide on clinical outcome.
herefore, although the NU-HIT trial confirmed the pos-
tive findings of the NAPA trial, still no definite recom-
endations on the perioperative intravenous rhNPs in
oronary bypass surgery patients can be drawn.
Another reservation on the acceptance of the routine use
f intravenous rhNPs in cardiovascular patients is that the
echanisms by which they should improve renal function
re still not well-understood. The overall effect is a delicate
alance of potentially beneficial and harmful effects on
idney function ( GFR). On the one hand, intravenous
hNPs will in general decrease blood pressure, leading to a
ecrease in renal plasma flow, which indeed was found with
hBNP (9). Because renal plasma flow is the main determi-
n
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April 27, 2010:1852–53 Cardiorenal Effects of Natriuretic Peptidesant driving GFR in heart failure patients (10), a decrease in
FR could be expected, but in that study, an increase in
FR was observed (9). The explanation for this might be
-fold. First, a direct effect of intravenous rhNPs on afferent
asodilation has been proposed although not clearly dem-
nstrated (9). Second, renal function is not only dependent
n renal plasma flow but on central venous pressure as well
10,11). Because intravenous rhNPs induce a clear reduction
n central venous pressure both by direct vasodilation, water
nd salt excretion, and decreased cardiac filling pressures,
his might improve renal perfusion pressure by reducing
renal afterload.” In particular in patients after coronary
ypass surgery, who are congested due to postoperative
levated cardiac filling pressures, this effect might outweigh
he effects on renal plasma flow and inhibition of the
AAS. Besides hemodynamic effects, rhNPs also have
ormonal effects on the kidney and the heart, through
nhibition of the RAAS. The RAAS inhibition might
reserve renal function in the long term, but in the short
erm, a decreased angiotensin II production would lead to
fferent vasodilation, a decreased glomerular pressure, and
herefore a decrease in GFR. In addition, intravenous
hNPs have multiple intrarenal effects on tubular function
nd several other vasoactive hormones, such as arginine
asopressin (9). These complex effects of intravenous rhNPs
n central and renal hemodynamic status as well as intra-
enal hormonal and functional actions might also explain
hy a positive effect on renal function was found in some
tudies, whereas in other studies no effect or even a
eterioration of renal function was found.
How can the findings of these studies be translated into
linical practice? The effects of nesiritide on renal function
nd clinical outcome in acute heart failure patients remain to
e established in an adequately powered study. Next year,
he outcomes of the ASCEND-HF (Acute Study of Clin-
cal Effectiveness of Nesiritide in Decompensated Heart
ailure) trial are expected (12). Data from the ASCEND-HF
rial will establish whether nesiritide improves clinical out-
ome in more than 7,000 patients with acute heart failure.
n patients undergoing coronary bypass surgery, the prom-
sing data of the NU-HIT trial together with the NAPA
rial should be sufficient to initiate a well-designed trial,
ith sufficient power to detect meaningful differences in
oth renal and clinical outcome. Given the complex and
ultiple counteracting effects of intravenous rhNPs on renal
nd cardiac function, the clinical outcome will probably
epend on the cause of renal and cardiac deterioration in the
ndividual patient. To study the effects of drugs that
rimarily aim to improve renal function on cardiovascular
c
nutcome is not only important from a clinical perspective
ut it will further enhance our understanding of its inter-
ction. As such, the present article adds to the unraveling of
he cardiorenal syndrome, which has long been neglected
1) but has received increasing recognition in recent years.
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